Management of cardiovascular disease in patients with systemic lupus erythematosus.

Expert Opinion on Pharmacotherapy
Paramarjan Piranavan, Andras Perl

Abstract

SLE is increasingly recognized as an important risk factor for cardiovascular disease. Premature CAD and several other cardiac manifestations are resulting in significant morbidity and premature death among young and older adults. There is a considerable unmet need for developing specific guidelines toward the primary and secondary prevention of cardiovascular disease in SLE patients. The authors describe the prevalence of various cardiovascular manifestations, associated with traditional and lupus-specific risk factors. They summarize the evidence behind various nonpharmacological and pharmacological options such as cardiac medications, antimalarials, anti-inflammatory, and immunosuppressant medications. There is considerable literature claiming that the traditional Framingham score used to calculate the risk in the general population would not clearly predict the 10-year risk among SLE patients as they do not include lupus-specific risk factors such as accelerated inflammation, immunometabolic changes, thrombosis, vasospasm, vasculitis, and endothelial dysfunction into account. Identifying potential risk factors among SLE patients and treating hyperlipidemia regardless of their risk scores may be the first step in reducing mo...Continue Reading

References

Feb 1, 1976·The American Journal of Medicine·M B UrowitzM A Ogryzlo
Feb 1, 1992·Annals of the Rheumatic Diseases·R CerveraM Ingelmo
May 1, 1989·Japanese Journal of Medicine·N InaseT Shiigai
Jan 12, 2001·Journal of the American College of Cardiology·N P AndrewsA A Quyyumi
May 14, 2003·Circulation·Donna ManciniAndrew R Marks
Dec 24, 2003·Scandinavian Journal of Rheumatology·Y K ChanH K Ng
Apr 13, 2005·Autoimmunity Reviews·Victor S GurevichYehuda Shoenfeld
Oct 7, 2005·Arthritis and Rheumatism·Karen H CostenbaderMatthew H Liang
Oct 13, 2005·Lupus·A DoriaM Petri
Jan 31, 2006·Journal of Cutaneous Pathology·A Bernard Ackerman
Sep 19, 2006·Immunity·Jacques Banchereau, Virginia Pascual
Feb 24, 2007·Vascular Health and Risk Management·Thein Htay, Ming W Liu
Apr 4, 2007·Rheumatology International·Karen H CostenbaderElizabeth W Karlson
Apr 29, 2008·American Heart Journal·Seema S SinhaWilliam F Fearon
Jun 26, 2008·Arthritis and Rheumatism·Kareem L GrahamPeggy P Ho
Aug 30, 2008·Annual Review of Medicine·Bradley A Maron, Joseph Loscalzo
Dec 24, 2008·Annals of the Rheumatic Diseases·G Ruiz-IrastorzaM A Khamashta
Apr 1, 2009·Arthritis and Rheumatism·Gudrun E NorbyUNKNOWN Assessment of Lescol in Renal Transplantation Study Group
Apr 28, 2009·Lupus·A CypieneA Laucevicius
May 1, 2008·Current Cardiology Reviews·Carlos Borelli Zeller, Simone Appenzeller
Mar 23, 2010·International Journal of Clinical Rheumatology·Carly Skamra, Rosalind Ramsey-Goldman
May 4, 2010·The Journal of Rheumatology·Sara Kaprove PennMary Chester M Wasko

❮ Previous
Next ❯

Citations

Sep 26, 2020·Frontiers in Immunology·Kathryn A WierengaJames J Pestka

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Biomarkers for Cardiovascular Risk Assessment

Sensitive and accurate biomarkers used in cardiovascular risk prediction can potentially be used to manage the risk of cardiovascular disease. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here. Discover the latest research on Biomarkers for Cardiovascular Risk Assessment here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.